pharma · Ingelheim, DE

Boehringer Ingelheim

Account opportunity

Not established

Relationship

Active signals

Trials as sponsor

Why this account matters

Boehringer Ingelheim

New trial — A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

New trialNCT04973163

52/100

Opportunity

Commercial fit11/25

Clinical timing19/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New phase 1 trial NCT04973163 posted by Boehringer Ingelheim: "A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation". New trial on a phase 1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 203 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Boehringer Ingelheim

New trial — A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

New trialNCT04111458

41/100

Opportunity

Commercial fit5/25

Clinical timing19/20

Biomarker need0/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New phase 1 trial NCT04111458 posted by Boehringer Ingelheim: "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)". New trial on a phase 1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 35 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

Trial	Phase	Testing language
NCT04111458 A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)	phase 1	—
NCT04973163 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation	phase 1	mol. elig.